During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant ...

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia ...

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly ...

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...